和黃醫藥(00013.HK)完成索樂匹尼布治療原發免疫性血小板減少症研究患者入組
和黃醫藥(00013.HK)公布,ESLIM-01研究已完成患者入組。ESLIM-01是一項在中國開展的索樂匹尼布治療成人原發免疫性血小板減少症的關鍵性III期臨床試驗。該研究的最後一名患者已於去年12月31日完成入組。
該研究共招募188名患者。研究的頂線結果預計將於今年下半年公布,並將隨即提交研究結果於適當的學術會議發表。 若取得積極結果,和黃醫藥將啟動計劃向中國國家藥品監督管理局遞交索樂匹尼布的上市許可申請。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.